

## XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.
- From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple indications in ten markets across the APAC region.

   XPOVIO® has been approved for health insurance coverage in the mainland of China, Taiwan market, Australia, Singapore and South Korea.

Shanghai and Hong Kong, PRC, March 5, 2025 — Antengene Corporation
Limited ( "Antengene", SEHK: 6996.HK), a leading innovative,
commercial-stage global biopharmaceutical company dedicated to
discovering, developing and commercializing first-in-class and/or bestin-class medicines for cancer, today announced that the Indonesia
National Agency of Drug and Food Control (BPOM) has approved a
New Drug Application (NDA) for XPOVIO® (selinexor) for three
indications: (1) In combination with bortezomib and dexamethasone for
the treatment of adult patients with multiple myeloma (MM) who have

received at least one prior therapy;(2) in combination with

dexamethasone for the treatment of adult patients with relapsed or

refractory MM (R/R MM) who have received at least four prior therapies

and whose disease is refractory to at least two proteasome inhibitors

(PIs), at least two immunomodulatory agents (IMiDs), and an anti-CD38

monoclonal antibody; and (3) as a monotherapy for the treatment of

adult patients with relapsed or refractory diffuse large B-cell lymphoma

(R/R DLBCL), not otherwise specified, including DLBCL arising from

follicular lymphoma, after at least two lines of systemic therapy who are

not eligible for haematopoietic cell transplant.

With a novel mechanism of action, XPOVIO® is the world's first approved

orally-available, selective XPO1 inhibitor, which has already been

approved in ten countries and regions in APAC, and has been included in

the national insurance schemes in five of these markets (the mainland of

China, Taiwan market, Australia, Singapore and South Korea).

The ASEAN region, with its steady economic growth and a population

exceeding 600 million, has become a market of significant potential for

global biomedical development. The accelerating aging population in

ASEAN has increased the overall disease burden on patients and local

communities, leading to a growing demand for novel therapeutics.

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室 Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China Tel: (86) 021 3250 1095

Currently, Antengene is actively expanding its presence into APAC

markets in efforts to introduce more innovative medicines to the ASEAN

region in the future, improving the level of healthcare in these regions

and benefiting more patients in need.

While bringing XPOVIO® to more APAC markets, Antengene is also

striving to expand the indications of XPOVIO®. Leveraging the drug's

novel mechanism of action, Antengene is currently developing multiple

combination regimens of XPOVIO® for the treatment of various

indications including myelofibrosis (MF) and endometrial cancer.

About XPOVIO® (selinexor)

XPOVIO® is the world's first approved orally-available, selective

inhibitor of the nuclear export protein XPO1. It offers a novel

mechanism of action, synergistic effects in combination

regimens, fast onset of action, and durable responses.

By blocking the nuclear export protein XPO1, XPOVIO® can

promote the intranuclear accumulation and activation of tumor

suppressor proteins and growth regulating proteins, and down-

regulate the levels of multiple oncogenic proteins. XPOVIO®

delivers its antitumor effects through three mechanistic

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室 Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China Tel: (86) 021 3250 1095



pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]).

## **About Antengene**

Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".

**漁車** 德琪医药

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia.

**Forward-looking statements** 

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of



these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.